KYTX KYVERNA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, KYVERNA THERAPEUTICS INC reported revenue of n/a, net income of −$38.3M and diluted EPS of −$0.63; for the fiscal year ended December 2025 revenue was n/a.
KYTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$170M, net income −$161M (margin n/a), EPS −$3.64
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$143M, net income −$127M (margin n/a), EPS −$3.33
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$62.4M, net income −$60.4M (margin n/a), EPS −$89.61
KYTX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$38.3M, EPS −$0.63
- Quarter ended Mar 31, 2026: revenue n/a, net income −$39.7M, EPS −$0.66
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$37.8M, EPS −$0.79
- Quarter ended Sep 30, 2025: revenue n/a, net income −$36.8M, EPS −$0.85
- Quarter ended Jun 30, 2025: revenue n/a, net income −$42.1M, EPS −$0.97
- Quarter ended Mar 31, 2025: revenue n/a, net income −$44.6M, EPS −$1.03
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$37.5M, EPS −$0.74
- Quarter ended Sep 30, 2024: revenue n/a, net income −$34.5M, EPS −$0.80
- Quarter ended Jun 30, 2024: revenue n/a, net income −$28.8M, EPS −$0.67
- Quarter ended Mar 31, 2024: revenue n/a, net income −$26.7M, EPS −$1.12
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$20.7M, EPS −$33.38
- Quarter ended Sep 30, 2023: revenue n/a, net income −$15.5M, EPS −$23.27
- Quarter ended Jun 30, 2023: revenue n/a, net income −$13.1M, EPS −$20.86
- Quarter ended Mar 31, 2023: revenue n/a, net income −$11.1M, EPS −$12.10
KYTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$154M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$114M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$52.4M, share buybacks n/a
KYTX balance sheet
- Jun 30, 2026: cash $31.8M, total assets $220M, total liabilities $54.3M, shareholders' equity $166M, long-term debt $24.9M
- Mar 31, 2026: cash $32.2M, total assets $257M, total liabilities $61.4M, shareholders' equity $196M
- Dec 31, 2025: cash $124M, total assets $294M, total liabilities $61.6M, shareholders' equity $232M, long-term debt $24.7M
- Sep 30, 2025: cash $34.2M, total assets $187M, total liabilities $35.2M, shareholders' equity $152M
- Jun 30, 2025: cash $53.4M, total assets $227M, total liabilities $42.1M, shareholders' equity $184M
- Mar 31, 2025: cash $56.9M, total assets $261M, total liabilities $36.6M, shareholders' equity $224M
- Dec 31, 2024: cash $96.6M, total assets $305M, total liabilities $38.1M, shareholders' equity $267M
- Sep 30, 2024: cash $105M, total assets $339M, total liabilities $36.5M, shareholders' equity $303M
Is KYTX profitable?
No. KYVERNA THERAPEUTICS INC lost $153M over the last four quarters.
What is KYTX's EPS?
Diluted earnings per share over the last four quarters were −$2.93; −$0.63 in the latest quarter.